110,300 Shares in Kyverna Therapeutics, Inc. $KYTX Acquired by Wesbanco Bank Inc.

Wesbanco Bank Inc. purchased a new position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 110,300 shares of the company’s stock, valued at approximately $952,000. Wesbanco Bank Inc. owned 0.18% of Kyverna Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Public Employees Retirement System of Ohio acquired a new position in Kyverna Therapeutics in the third quarter valued at $28,000. Qube Research & Technologies Ltd purchased a new position in shares of Kyverna Therapeutics in the 2nd quarter worth about $43,000. Rhumbline Advisers lifted its stake in shares of Kyverna Therapeutics by 22.0% in the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after purchasing an additional 5,694 shares in the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of Kyverna Therapeutics during the 3rd quarter worth about $77,000. Finally, Bank of America Corp DE grew its holdings in shares of Kyverna Therapeutics by 41.6% during the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after purchasing an additional 6,400 shares during the period. 18.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on KYTX shares. Wall Street Zen cut shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Kyverna Therapeutics in a report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Wednesday. Finally, JPMorgan Chase & Co. cut their price objective on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $30.00.

Kyverna Therapeutics Price Performance

KYTX stock opened at $8.44 on Monday. Kyverna Therapeutics, Inc. has a twelve month low of $2.52 and a twelve month high of $13.67. The company has a current ratio of 8.15, a quick ratio of 8.15 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $513.07 million, a P/E ratio of -2.57 and a beta of 1.96. The firm has a 50 day simple moving average of $8.79 and a 200-day simple moving average of $8.60.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.09. On average, equities research analysts predict that Kyverna Therapeutics, Inc. will post -2.78 earnings per share for the current fiscal year.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.